Literature DB >> 19029958

Reflecting on 25 years with MYC.

Natalie Meyer1, Linda Z Penn.   

Abstract

Just over 25 years ago, MYC, the human homologue of a retroviral oncogene, was identified. Since that time, MYC research has been intense and the advances impressive. On reflection, it is astonishing how each incremental insight into MYC regulation and function has also had an impact on numerous biological disciplines, including our understanding of molecular oncogenesis in general. Here we chronicle the major advances in our understanding of MYC biology, and peer into the future of MYC research.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19029958     DOI: 10.1038/nrc2231

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  694 in total

1.  Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma.

Authors:  Andrés E Quesada; L Jeffrey Medeiros; Parth A Desai; Pei Lin; Jason R Westin; Huda M Hawsawi; Peng Wei; Guilin Tang; Adam C Seegmiller; Nishitha M Reddy; C Cameron Yin; Wei Wang; Jie Xu; Roberto N Miranda; Zhuang Zuo; Shaoying Li
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

2.  Nucleophosmin is essential for c-Myc nucleolar localization and c-Myc-mediated rDNA transcription.

Authors:  Z Li; S R Hann
Journal:  Oncogene       Date:  2012-06-04       Impact factor: 9.867

3.  TCEAL7 inhibition of c-Myc activity in alternative lengthening of telomeres regulates hTERT expression.

Authors:  Kyle Lafferty-Whyte; Alan Bilsland; Stacey F Hoare; Sharon Burns; Nadia Zaffaroni; Claire J Cairney; William Nicol Keith
Journal:  Neoplasia       Date:  2010-05       Impact factor: 5.715

4.  Spontaneous transformation of murine epithelial cells requires the early acquisition of specific chromosomal aneuploidies and genomic imbalances.

Authors:  Hesed M Padilla-Nash; Karen Hathcock; Nicole E McNeil; David Mack; Daniel Hoeppner; Rea Ravin; Turid Knutsen; Raluca Yonescu; Danny Wangsa; Kathleen Dorritie; Linda Barenboim; Yue Hu; Thomas Ried
Journal:  Genes Chromosomes Cancer       Date:  2011-12-08       Impact factor: 5.006

5.  Genetic variation at chromosome 8q24 in osteosarcoma cases and controls.

Authors:  Lisa Mirabello; Sonja I Berndt; Guillermo F Seratti; Laurie Burdett; Meredith Yeager; Salma Chowdhury; Kedest Teshome; Arinze Uzoka; Chester Douglass; Richard B Hayes; Robert N Hoover; Sharon A Savage
Journal:  Carcinogenesis       Date:  2010-06-07       Impact factor: 4.944

6.  myc maintains embryonic stem cell pluripotency and self-renewal.

Authors:  Natalia V Varlakhanova; Rebecca F Cotterman; Wilhelmine N deVries; Judy Morgan; Leah Rae Donahue; Stephen Murray; Barbara B Knowles; Paul S Knoepfler
Journal:  Differentiation       Date:  2010-05-27       Impact factor: 3.880

Review 7.  PIM1: a promising target in patients with triple-negative breast cancer.

Authors:  Wen Zhao; RuiYue Qiu; Pan Li; Jin Yang
Journal:  Med Oncol       Date:  2017-07-18       Impact factor: 3.064

8.  A framework for identification of actionable cancer genome dependencies in small cell lung cancer.

Authors:  Martin L Sos; Felix Dietlein; Martin Peifer; Jakob Schöttle; Hyatt Balke-Want; Christian Müller; Mirjam Koker; André Richters; Stefanie Heynck; Florian Malchers; Johannes M Heuckmann; Danila Seidel; Patrick A Eyers; Roland T Ullrich; Andrey P Antonchick; Viktor V Vintonyak; Peter M Schneider; Takashi Ninomiya; Herbert Waldmann; Reinhard Büttner; Daniel Rauh; Lukas C Heukamp; Roman K Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-03       Impact factor: 11.205

9.  Targeting MYC sensitizes malignant mesothelioma cells to PAK blockage-induced cytotoxicity.

Authors:  Yinfei Tan; Eleonora Sementino; Jonathan Chernoff; Joseph R Testa
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

Review 10.  Mechanisms underlying the formation of induced pluripotent stem cells.

Authors:  Federico González; Danwei Huangfu
Journal:  Wiley Interdiscip Rev Dev Biol       Date:  2015-09-18       Impact factor: 5.814

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.